Back to Search
Start Over
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
- Source :
-
Blood cancer journal [Blood Cancer J] 2021 Jan 07; Vol. 11 (1), pp. 4. Date of Electronic Publication: 2021 Jan 07. - Publication Year :
- 2021
- Subjects :
- Humans
Janus Kinases antagonists & inhibitors
Multivariate Analysis
Nitriles
Protein Kinase Inhibitors administration & dosage
Pyrazoles administration & dosage
Pyrimidines
Risk Factors
Treatment Outcome
Primary Myelofibrosis drug therapy
Protein Kinase Inhibitors therapeutic use
Pyrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2044-5385
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Blood cancer journal
- Publication Type :
- Report
- Accession number :
- 33414394
- Full Text :
- https://doi.org/10.1038/s41408-020-00392-1